Aaron Samuel Meyer

Aaron Samuel Meyer

Auto-generated profile, based on publicly available information

Aaron Samuel Meyer

Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90024, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2013 in Science Signaling
Verified
Journal Article
Open access
PDF file
AMAaron S. Meyer
Aaron S. Meyer
MMMiles Miller
Miles Miller
FGFrank B. Gertler
Frank B. Gertler
DLDouglas A. Lauffenburger
Douglas A. Lauffenburger
The relationship between drug resistance, changes in signaling, and emergence of an invasive phenotype is well appreciated, but the underlying mechanisms are not well understood. Using machine learning analysis applied to the Cancer Cell Line Encyclopedia database, we identified expression of AXL, the gene that encodes the epithelial-to-mesenchymal transition (EMT)–associated receptor tyrosine kinase (RTK) AXL, as exceptionally predictive of lack of response to ErbB family receptor–targeted inhibitors. Activation of EGFR (epidermal growth factor receptor) transactivated AXL, and this ligand-independent AXL activity diversified EGFR-induced signaling into additional downstream pathways beyond those triggered by EGFR alone. AXL-mediated signaling diversification was required for EGF (epidermal growth factor)–elicited motility responses in AXL-positive TNBC (triple-negative breast cancer) cells. Using cross-linking coimmunoprecipitation assays, we determined that AXL associated with EGFR, other ErbB receptor family members, MET (hepatocyte growth factor receptor), and PDGFR (platelet-derived growth factor receptor) but not IGF1R (insulin-like growth factor 1 receptor) or INSR (insulin receptor). From these AXL interaction data, we predicted AXL-mediated signaling synergy for additional RTKs and validated these predictions in cells. This alternative mechanism of receptor activation limits the use of ligand-blocking therapies and indicates against therapy withdrawal after acquired resistance. Further, subadditive interaction between EGFR- and AXL-targeted inhibitors across all AXL-positive TNBC cell lines may indicate that increased abundance of EGFR is principally a means to transactivation-mediated signaling.

6 November 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
Chang Han LeeChang Han Lee
Chang Han Lee
Tae Hyun KangTae Hyun Kang
Tae Hyun Kang
OGOphélie Godon
Ophélie Godon
MWMakiko Watanabe
Makiko Watanabe
GDGeorge Delidakis
George Delidakis
GGGeorge Georgiou
George Georgiou
The pharmacokinetic properties of antibodies are largely dictated by the pH-dependent binding of the IgG fragment crystallizable (Fc) domain to the human neonatal Fc receptor (hFcRn). Engineered Fc domains that confer a longer circulation half-life by virtue of more favorable pH-dependent binding to hFcRn are of great therapeutic interest. Here we developed a pH Toggle switch Fc variant containing the L309D/Q311H/N434S (DHS) substitutions, which exhibits markedly improved pharmacokinetics relative to both native IgG1 and widely used half-life extension variants, both in conventional hFcRn transgenic mice and in new knock-in mouse strains. engineered specifically to recapitulate all the key processes relevant to human antibody persistence in circulation, namely: (i) physiological expression of hFcRn, (ii) the impact of hFcγRs on antibody clearance and (iii) the role of competing endogenous IgG. DHS-IgG retains intact effector functions, which are important for the clearance of target pathogenic cells and also has favorable developability.

4 June 2012 in Journal of Cell Biology
Verified
Journal Article
Open access
AMAaron S. Meyer
Aaron S. Meyer
SHShannon K. Hughes-Alford
Shannon K. Hughes-Alford
JKJennifer E. Kay
Jennifer E. Kay
ACAmalchi Castillo
Amalchi Castillo
Alan WellsAlan Wells
Alan Wells
DLDouglas A. Lauffenburger
Douglas A. Lauffenburger
Growth factor–induced migration is a critical step in the dissemination and metastasis of solid tumors. Although differences in properties characterizing cell migration on two-dimensional (2D) substrata versus within three-dimensional (3D) matrices have been noted for particular growth factor stimuli, the 2D approach remains in more common use as an efficient surrogate, especially for high-throughput experiments. We therefore were motivated to investigate which migration properties measured in various 2D assays might be reflective of 3D migratory behavioral responses. We used human triple-negative breast cancer lines stimulated by a panel of receptor tyrosine kinase ligands relevant to mammary carcinoma progression. Whereas 2D migration properties did not correlate well with 3D behavior across multiple growth factors, we found that increased membrane protrusion elicited by growth factor stimulation did relate robustly to enhanced 3D migration properties of the MDA-MB-231 and MDA-MB-157 lines. Interestingly, we observed this to be a more reliable relationship than cognate receptor expression or activation levels across these and two additional mammary tumor lines.

14 May 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MMMiles Miller
Miles Miller
AMAaron S. Meyer
Aaron S. Meyer
MBMichael T. Beste
Michael T. Beste
ZLZainab Lasisi
Zainab Lasisi
SRSonika Reddy
Sonika Reddy
DLDouglas A. Lauffenburger
Douglas A. Lauffenburger
Significance: Regulated cell-surface proteolysis underpins processes of cellular migration in both physiological and pathological contexts. However, comprehending how multiple proteolytic events cohesively integrate to yield context-dependent cellular behavior remains a challenge. Here we present an experimental/computational paradigm for analyzing networks of protease activities that interface with signaling pathways to influence cellular migration in the invasive disease of endometriosis. We find that induced cellular migration is a quantitative consequence of positive feedback through ligand release and negative feedback through receptor shedding, which furthermore drives rapid resistance to kinase inhibitor treatment. Targeted clinical proteomics confirms dysregulated proteolysis in endometriosis.

10 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
SGSean M. Gross
Sean M. Gross
FMFarnaz Mohammadi
Farnaz Mohammadi
CSCrystal Sanchez-Aguila
Crystal Sanchez-Aguila
PZPaulina J. Zhan
Paulina J. Zhan
TLTiera A. Liby
Tiera A. Liby
LHLaura M. Heiser
Laura M. Heiser
Identifying effective therapeutic treatment strategies is a major challenge to improving outcomes for patients with breast cancer. To gain a comprehensive understanding of how clinically relevant anti-cancer agents modulate cell cycle progression, here we use genetically engineered breast cancer cell lines to track drug-induced changes in cell number and cell cycle phase to reveal drug-specific cell cycle effects that vary across time. We use a linear chain trick (LCT) computational model, which faithfully captures drug-induced dynamic responses, correctly infers drug effects, and reproduces influences on specific cell cycle phases. We use the LCT model to predict the effects of unseen drug combinations and confirm these in independent validation experiments. Our integrated experimental and modeling approach opens avenues to assess drug responses, predict effective drug combinations, and identify optimal drug sequencing strategies.

21 November 2017 in Integrative Biology
Verified
Journal Article
Open access
PDF file
ASAlyssa D. Schwartz
Alyssa D. Schwartz
LBLauren E. Barney
Lauren E. Barney
LJLauren E. Jansen
Lauren E. Jansen
TNThuy V. Nguyen
Thuy V. Nguyen
CHChristopher L. Hall
Christopher L. Hall
SPShelly R. Peyton
Shelly R. Peyton
Drug response screening, gene expression, and kinome signaling were combined across biomaterial platforms to combat adaptive resistance to sorafenib.